22nd Century Group is scheduled to report its third quarter 2026 results on November 16, 2026, after releasing preliminary figures in late October. Preliminary results point to net revenue of about $4.8 million, up 66% from $2.9 million in the second quarter of 2026.

DarkHorse Technologies (DRK) is expected to report its third-quarter 2026 results around November 16–17, 2026, its first full quarter under its new name following the September 2026 rebrand from Sphere 3D Corp. Consensus estimates point to a narrower loss per share, with forecasts ranging from roughly $0.26 to $0.42, on revenue near $7.0 million for the quarter.

Sonoma Pharmaceuticals reported record quarterly revenue of $6.4 million , up 60% year over year and above the roughly $4.99 million consensus estimate. Net loss narrowed sharply to $0.3 million , or $0.09 per share, compared with a $1.2 million loss, or $0.76 per share, in the prior-year quarter.

Longeveron Inc. (NASDAQ: LGVN) is expected to report its third-quarter 2026 results in early November 2026, after the U.S. market close, followed by a conference call. Wall Street consensus points to a net loss near $1.95 per share on revenue of approximately $0.56 million , a sharp improvement from a loss of $3.90 per share on $0.14 million in revenue a year earlier.

AquaBounty Technologies reported results for its third quarter of fiscal 2026 (the three months ended September 30, 2026) on November 3, 2026. The company continues to operate in a strategic wind-down, having ceased active fish-rearing operations after the sale of its Indiana and Canadian farm assets.

Flux Power reported fiscal first-quarter 2027 revenue of $6.8 million , down from $13.2 million a year earlier and below the $8.2 million posted in the prior quarter. Net loss widened to $3.2 million , or $0.15 per share, compared with a net loss of $2.6 million, or $0.15 per share, in the same period last year.

Zepp Health guided third quarter of 2026 net revenue to a range of $68.0 million to $73.0 million, implying a year-over-year decline of roughly 4% to 10%. The comparison is unusually difficult: revenue in the third quarter of 2025 jumped 78.5% year over year to $75.8 million, creating a high base.

EnerSyn Global Inc. (ESYN), formerly HWH International, reported results for the third quarter ended September 30, 2026, on November 3, 2026. The company posted a net loss of roughly $0.04 per share, essentially matching the year-ago quarter's per-share loss.

Key Tronic reported first quarter fiscal 2027 net sales of $98.7 million , essentially flat versus $98.8 million in the prior-year period. Net loss widened to $7.5 million , or $0.69 per share , from a net loss of $2.3 million, or $0.21 per share, a year earlier.

Revenue reached $9.1 million in the third quarter of 2026, up 183% year over year from $3.2 million and 22% sequentially, driven by product sales that grew more than fourfold versus a year ago. Net loss narrowed sharply to $1.5 million, or $0.10 per diluted ADS (American Depositary Share), compared with a $9.8 million loss in the prior quarter.

Cohen & Company (COHN) is expected to report its third quarter 2026 results around November 4, 2026 , before the market opens. Analyst consensus points to fully diluted earnings per share (EPS) of $0.42 , with a single-analyst revenue estimate near $41 million .

Consolidated revenue rose 16% year over year to $8.7 million , exceeding the roughly $7.7 million consensus estimate. The company posted a net loss of $267,000 , or $0.01 per share , in line with analyst expectations and down from a $303,000 profit in the prior-year quarter.

Net investment income (NII), the income a business development company earns from its portfolio after expenses, fell to $0.17 per share , down from $0.32 per share in the prior quarter. Net asset value (NAV), or the per-share value of the company's investments, declined 6.9% to $7.40 per share , pressured by $6.6 million in realized and unrealized investment losses.

Biomea Fusion is expected to report third-quarter 2026 results on Tuesday, November 3, 2026, after the market close. Wall Street consensus points to a net loss of roughly $0.18 to $0.23 per share, compared with a loss of $0.27 per share in the same period a year earlier.

Werewolf Therapeutics is expected to report third-quarter 2026 results in early November, covering the three months ended September 30, 2026. Wall Street consensus points to a net loss of approximately $0.22 per share for Q3 2026, narrower than the $0.36 per-share loss reported in the same period a year ago.

Comscore reported third-quarter 2026 revenue of $76.2 million , down 14.3% year over year; excluding the divested Movies business, revenue declined a more moderate 4.1% on a pro forma basis. The company posted a generally accepted accounting principles (GAAP) net loss of $65.5 million , or $4.26 per share , driven primarily by a $57.3 million non-cash goodwill impairment charge and $5.5 million in restructuring expenses.

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) is scheduled to report its third quarter 2026 financial results and provide a company update after the market close on Tuesday, November 10, 2026, followed by a conference call at 4:30 p.m. Eastern Time. The report lands as the Nashville-based biopharmaceutical company pivots toward a development-focused, rare-disease model after agreeing to sell its commercial brand portfolio to Apotex for $100 million in cash.

CPS Technologies reported record quarterly revenue of $8.9 million for its fiscal third quarter ended September 26, 2026, up from $8.8 million a year earlier. Diluted earnings per share (EPS) came in at $0.02, above the $0.01 consensus estimate, while net income rose to $0.3 million from $0.2 million in the prior-year quarter.

Chegg reported third quarter 2026 total net revenue of $46.5 million , a decline of roughly 40% year over year but above the consensus estimate of about $43.5 million. Non-GAAP (non-Generally Accepted Accounting Principles) loss per share of $0.05 beat the consensus estimate of a $0.09 loss.

Total revenue reached $25.2 million, up 44% year over year, slightly ahead of the $25.18 million consensus estimate. Non-GAAP earnings per share (EPS) came in at $0.12, beating the $0.11 analyst estimate by one cent.